AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 20853611
Drug: V1 -
RxNorm normalized name: SODIUM MOLYBDATE (V1) 50MIL INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: V1 - bortezomib 1.3 mg/m2 intravenously on days 1, 4, 8, and 11 of a 21-day cycle
Trial: 20853611
Drug: V2 -
RxNorm normalized name: rhuFab V2
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: V2 - bortezomib 1.3 mg/m2 intravenously on days 1, 4, 8, and 11, melphalan 20 mg orally on day 2 of a 28-day cycle
Trial: 1959461
Drug: Prazosin (alpha-adrenergic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prazosin (alpha-adrenergic blocker)
Trial: 28035659
Drug: Patch testing
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patch testing for food additives
Trial: 19920724
Drug: Low-frequency pulsed
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-frequency pulsed electromagnetic field (PEMF) therapy
Trial: 26440233
Drug: Ketamine 0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine 0.8 mg/kg
Trial: 9034275
Drug: Prophylactic ranitidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic ranitidine treatment for 4 days
Trial: 9034275
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no ranitidine treatment)
Trial: 9034275
Drug: Surfactant treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surfactant treatment for infant respiratory distress syndrome
Trial: 22230963
Drug: LigaSure LF1212
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LigaSure LF1212 (L)
Trial: 20378080
Drug: Mipomersen 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mipomersen 100 mg/week and higher
Trial: 20378080
Drug: Mipomersen 200
RxNorm normalized name: mipomersen 200 mg/mL subcutaneous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mipomersen 200 mg/week (13-week cohort)
Trial: 15791113
Drug: Intravenous acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous acetaminophen (1 g)
Trial: 8748429
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg of nefazodone (NEF) twice daily
Trial: 8748429
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg of lorazepam (LOR) twice daily
Trial: 8748429
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 2 mg of LOR and 200 mg of NEF (LOR+NEF) twice daily
Trial: 8748429
Drug: Placebo (PLA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (PLA) twice daily
Trial: 31238161
Drug: Abatacept therapy
RxNorm normalized name: Abatacept
DrugBank: Abatacept (DB01281)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Abatacept therapy (weekly or every other week administration)
Trial: 31238161
Drug: Abatacept therapy
RxNorm normalized name: Abatacept
DrugBank: Abatacept (DB01281)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Abatacept therapy
Trial: 31238161
Drug: Abatacept therapy
RxNorm normalized name: Abatacept
DrugBank: Abatacept (DB01281)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Abatacept therapy (every 4 weeks)
Trial: 27307704
Drug: Paliperidone palmitate
RxNorm normalized name: Paliperidone Palmitate
DrugBank: Paliperidone (DB01267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paliperidone palmitate 3-monthly injections (PP-3M)
Trial: 17560664
Drug: Acetaminophen +
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen + diphenhydramine + pseudoephedrine (Group-1)
Trial: 17560664
Drug: Acetaminophen only
RxNorm normalized name: Acetaminophen only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen only (Group-2)
Trial: 11597378
Drug: Oral pilocarpine
RxNorm normalized name: Pilocarpine
DrugBank: Pilocarpine (DB01085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral pilocarpine (OP)
Trial: 9855155
Drug: Topical 0.25%
RxNorm normalized name: permethrin topical 0.25% topical kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 0.25% verapamil (single drop)
Trial: 9855155
Drug: Topical 0.25%
RxNorm normalized name: permethrin topical 0.25% topical kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 0.25% verapamil (2-week administration)
Trial: 9855155
Drug: Placebo (2-week
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (2-week administration)
Trial: 2925973
Drug: Insight-oriented marital
RxNorm normalized name: barbital
DrugBank: Barbital (DB01483)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insight-oriented marital therapy (IOMT)
Trial: 2925973
Drug: Treatment-on-demand (TOD)
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-on-demand (TOD) waiting-list control group
Trial: 18321745
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of 0.01% raspberry ketone (RK)
Trial: 14522625
Drug: 2% licorice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% licorice topical gel
Trial: 14522625
Drug: 1% licorice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% licorice topical gel
Trial: 14522625
Drug: Base gel
RxNorm normalized name: Orabase Gel-B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Base gel (control)
Trial: 1599063
Drug: Transdermal hyoscine
RxNorm normalized name: HYOSCINE HYDROBROMIDE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal hyoscine (Scopoderm TTS CIBA)
Trial: 27799756
Drug: Ectoin® inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ectoin® inhalation solution
Trial: 20035240
Drug: Histone deacetylase
RxNorm normalized name: Histone deacetylase inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Histone deacetylase inhibitor vorinostat
Trial: 15823183
Drug: Fluticasone administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone administered twice daily
Trial: 15823183
Drug: Fluticasone administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone administered once daily
Trial: 11956267
Drug: Adjuvant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant therapy with Melacine vaccine
Trial: 11956267
Drug: Adjuvant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant therapy with Melacine vaccine among HLA-A2-positive and/or HLA-C3-positive patients
Trial: 322821
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g amoxycillin plus 1 g probenecid
Trial: 322821
Drug: 3 g
RxNorm normalized name: Molds 3 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g amoxycillin plus 1 g probenecid
Trial: 26999837
Drug: Systemic steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic steroid + intratympanic steroid as supplementary treatment (group A)
Trial: 26999837
Drug: Initial intratympanic
RxNorm normalized name: ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Initial intratympanic steroid (group B)
Trial: 26999837
Drug: Intratympanic steroid
RxNorm normalized name: ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intratympanic steroid as supplementary treatment (12 patients in group A)
Trial: 15151263
Drug: rhGH therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhGH therapy (0.25 IU/kg subcutaneously 3x/week after each dialysis session)
Trial: 9294877
Drug: Creatine supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine supplementation (18.75 g creatine monohydrate daily for 5 days prior to and 2.25 g creatine daily during testing)
Trial: 9294877
Drug: Placebo (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (5 g of calcium chloride daily for 5 days prior to the first set of work bouts)
Trial: 29550238
Drug: High-flow therapy
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-flow therapy with 'rescue' CPAP backup
Trial: 29550238
Drug: High-flow therapy
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-flow therapy without 'rescue' CPAP backup
Trial: 23662515
Drug: Unbalanced solutions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unbalanced solutions in infusion therapy
Trial: 23662515
Drug: Balanced solutions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balanced solutions in infusion therapy
Trial: 20230331
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid 5mg tablets daily for 4 weeks
Trial: 12138953
Drug: Osteopathic manipulative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osteopathic manipulative treatment (OMT) for 14 weeks
Trial: 2143104
Drug: Trospectomycin (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trospectomycin (75 to 1,000 mg)
Trial: 2143104
Drug: Trospectomycin (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trospectomycin (600 mg and above)
Trial: 2143104
Drug: Trospectomycin (1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trospectomycin (1,000 mg)
Trial: 841605
Drug: Irradiation under
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Irradiation under 95% O2 plus 5% CO2 inhalation
Trial: 30958319
Drug: Cathodal transcranial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cathodal transcranial direct current stimulation over the contralesional cerebellar hemisphere + cathodal transcutaneous spinal direct current stimulation in combination with robotic training
Trial: 30958319
Drug: Cathodal transcranial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cathodal transcranial direct current stimulation over the ipsilesional cerebellar hemisphere + cathodal transcutaneous spinal direct current stimulation in combination with robotic training
Trial: 25877495
Drug: B vitamin
RxNorm normalized name: B-50 Hi Potency B Vitamins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B vitamin supplementation (folic acid 0.8 mg, vitamin B-6 20 mg, vitamin B-12 0.5 mg)
Trial: 24032554
Drug: ixekizumab 10,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ixekizumab 10, 25, 75 or 150 mg subcutaneously
Trial: 19538811
Drug: Calcium carbonate
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium carbonate (1000 mg Ca)
Trial: 19538811
Drug: Calcium citrate
RxNorm normalized name: Calcium Citrate
DrugBank: Calcium sulfate (DB15533)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium citrate (1000 mg Ca)
Trial: 19538811
Drug: Potassium citrate
RxNorm normalized name: Potassium Citrate
DrugBank: Potassium (DB14500)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Potassium citrate (2250 mg K)
Trial: 17091418
Drug: Topical lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical lidocaine treatment
Trial: 11894976
Drug: Alcohol ingestion
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alcohol ingestion (0.45 g ethanol/kg)
Trial: 9592984
Drug: Aprotinin (high-dose,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aprotinin (high-dose, continuous intravenous infusion)
Trial: 3203010
Drug: Monthly maintenance
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly maintenance therapy consisting of thioguanine 100 mg/m2 twice daily and etoposide 100 mg/m2 twice daily (days 1-5) alternating with CCNU 50 mg/m2 once to a total of 6 courses.
Trial: 28463149
Drug: Long-term ADT
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term ADT (LTAD: 4 months of flutamide 250 mg 3 times per day and goserelin 3.6 mg per month plus an additional 24 months of monthly goserelin)
Trial: 28463149
Drug: Short-term ADT
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term ADT (STAD: 4 months of flutamide 250 mg 3 times per day and goserelin 3.6 mg per month)
Trial: 23540577
Drug: Physical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical therapy program
Trial: 8797346
Drug: Gd-BOPTA (E7155)
RxNorm normalized name: Gd-HPDO3A
DrugBank: Gadoteridol (DB00597)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gd-BOPTA (E7155) low dose (0.025 mmol/kg)
Trial: 8797346
Drug: Gd-BOPTA (E7155)
RxNorm normalized name: Gd-HPDO3A
DrugBank: Gadoteridol (DB00597)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gd-BOPTA (E7155) medium dose (0.05 mmol/kg)
Trial: 8797346
Drug: Gd-BOPTA (E7155)
RxNorm normalized name: Gd-HPDO3A
DrugBank: Gadoteridol (DB00597)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gd-BOPTA (E7155) high dose (0.1 mmol/kg)
Trial: 1514709
Drug: Iomeprol, 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iomeprol, 150 mg iodine/mL
Trial: 1514709
Drug: Iopamidol, 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iopamidol, 150 mg iodine/mL
Trial: 31968102
Drug: HDL-C raising
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HDL-C raising genetic variants in the gene locus of CETP inhibitors
Trial: 31582195
Drug: Supportive Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supportive Therapy for Cognitively Impaired
Trial: 26963909
Drug: OEPA chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OEPA chemotherapy
Trial: 20075695
Drug: Fiber supplementation
RxNorm normalized name: fiber
DrugBank: Calcium polycarbophil (DB14684)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fiber supplementation for fecal incontinence (FI), specific dosage and duration not mentioned.
Trial: 17327409
Drug: Eltrombopag (5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eltrombopag (5, 10, 25, 30, 50, and 75 mg)
Trial: 16263675
Drug: Special Operations
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Special Operations Forces Tactical Tourniquet (Tactical Medical Solutions, LLC)
Trial: 8672759
Drug: Prednisolone 30
RxNorm normalized name: prednisolone 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone 30 mg daily for 3 weeks, 15 mg for 1 week, and no prednisolone for 2 weeks prior to lymphoblastoid IFN therapy (Group 1)
Trial: 8672759
Drug: Prednisolone 40
RxNorm normalized name: prednisolone 40 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone 40 mg daily for 2 weeks, 30 mg for 2 weeks, 20 mg for 2 weeks, and no prednisolone for 2 weeks prior to INF alpha‐2a therapy (Group 2)
Trial: 8672759
Drug: Higher dose
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher dose of prednisolone (40 mg)
Trial: 6402387
Drug: 1.0 mg
RxNorm normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg dl-norgestrel and 0.1 mg ethinylestradiol (EE) administered orally at 36 hours after LH peak and again at 48 hours
Trial: 6402387
Drug: Endometrial biopsies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endometrial biopsies from treatment cycle
Trial: 26773183
Drug: Bismuth-containing quadruple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bismuth-containing quadruple therapy (QT) for 10 days
Trial: 26773183
Drug: Sequential therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential therapy (ST) for 10 days
Trial: 26773183
Drug: Concomitant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concomitant therapy (CT) for 10 days
Trial: 18614781
Drug: Standard oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard oxygen therapy (367 patients)
Trial: 15642905
Drug: MRI scans
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MRI scans before antiepileptic medication and follow-up MRI scans after 1, 2 to 3, and 5 years of treatment
Trial: 12145071
Drug: Forearm IVRA
RxNorm normalized name: Ivra
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Forearm IVRA with 100 mg lidocaine and 10 mg ketorolac
Trial: 12145071
Drug: Upper Arm
RxNorm normalized name: A And D Medical UA-651 Upper Arm BPM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Upper Arm IVRA with 200 mg lidocaine and 20 mg ketorolac
Trial: 7733838
Drug: Levorotatory form
RxNorm normalized name: methyldopa (levorotatory)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levorotatory form of hydroxytryptophan (1000 mg/d)
Trial: 22495787
Drug: UC781 vaginal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UC781 vaginal gel
Trial: 19369187
Drug: No additional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No additional treatment (Control group, n = 46)
Trial: 15024596
Drug: Double Stapled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double Stapled Trans‐Anal Rectal Resection (STARR Group)
Trial: 11597813
Drug: Accelerated Hyperfractionated
RxNorm normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Accelerated Hyperfractionated (AH) whole‐brain radiation therapy (1.6 Gy b.i.d. to 54.4 Gy)
Trial: 11597813
Drug: Accelerated Fractionation
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Accelerated Fractionation (AF) whole‐brain radiation therapy (3 Gy q.d. to 30 Gy)
Trial: 9688452
Drug: Ceftazidime 3
RxNorm normalized name: ceftazidime 30 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftazidime 3 g daily + amikacin (reference regimen)
Trial: 8082347
Drug: Bolus rt-PA
RxNorm normalized name: rt-PA
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bolus rt-PA (0.6 mg/kg/15 min, maximum of 50 mg)
Trial: 8082347
Drug: 2-h rt-PA
RxNorm normalized name: rt-PA
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2-h rt-PA (100 mg over 2 h)
Trial: 1091965
Drug: Buffered acetylsalicylic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buffered acetylsalicylic acid (ASA) preparation
Trial: 1091965
Drug: Plain acetylsalicylic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plain acetylsalicylic acid (ASA) tablets
Trial: 30159738
Drug: Monovisc™ (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monovisc™ (4 ml single injection)
Trial: 30159738
Drug: Saline (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline (4 ml injection of 0.9% saline)
Trial: 25269659
Drug: Pump 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pump 2 (Asante Snap Insulin Pump)
Trial: 22834767
Drug: Aliskiren 300
RxNorm normalized name: aliskiren 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aliskiren 300 mg once daily for 6 weeks
Trial: 21270359
Drug: 15 μg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 μg/d cholecalciferol (D3) supplementation
Trial: 21270359
Drug: 5 μg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 μg/d cholecalciferol (D3)
Trial: 21270359
Drug: 10 μg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 μg/d cholecalciferol (D3)
Trial: 17137511
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg intravenous adenosine
Trial: 12672714
Drug: Baseline (BL)
RxNorm normalized name: BL-1020
DrugBank: BL-1020 (DB05687)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline (BL) diet (35% fat, 14% SFA, 13% MUFA, 8% PUFA, 147 mg cholesterol/1000 kcal)
Trial: 12672714
Drug: Reduced-fat (RF)
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reduced-fat (RF) diet (26% fat, 4% SFA, 11% MUFA, 11% PUFA, 45 mg cholesterol/1000 kcal)
Trial: 12672714
Drug: Low-fat (LF)
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-fat (LF) diet (15% fat, 5% SFA, 5% MUFA, 3% PUFA, 35 mg cholesterol/1000 kcal)
Trial: 1418778
Drug: Zidovudine +
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zidovudine + Acyclovir (800 mg every 6 h)
Trial: 6396834
Drug: Single-dose trimethoprim-sulfamethoxazole
RxNorm normalized name: sulfamethoxazole / trimethoprim
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose trimethoprim-sulfamethoxazole (4 tablets)
Trial: 6396834
Drug: 3-day trimethoprim-sulfamethoxazole
RxNorm normalized name: sulfamethoxazole / trimethoprim
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-day trimethoprim-sulfamethoxazole (2 tablets twice daily)
Trial: 6396834
Drug: 10-day trimethoprim-sulfamethoxazole
RxNorm normalized name: sulfamethoxazole / trimethoprim
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-day trimethoprim-sulfamethoxazole (2 tablets twice daily)
Trial: 26466321
Drug: Bioimpedance intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bioimpedance intervention group with increased dialysate glucose prescription
Trial: 9501747
Drug: Paroxetine (33.9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine (33.9 mg daily)
Trial: 9501747
Drug: Imipramine (162.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipramine (162.5 mg daily)
Trial: 7663312
Drug: ritanserin 5
RxNorm normalized name: ketanserin
DrugBank: Ketanserin (DB12465)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ritanserin 5 mg/day